📊 JNJ Key Takeaways
Is Johnson & Johnson (JNJ) a Good Investment?
Johnson & Johnson demonstrates exceptional financial health with industry-leading profitability (28.5% net margin, 34.6% operating margin) and robust cash generation ($19.7B free cash flow). The 90.6% YoY net income growth, combined with strong fundamentals (210x interest coverage, 0.51x debt/equity), reflects operational excellence and disciplined capital management in a stable pharmaceutical business.
Johnson & Johnson shows high-quality fundamentals with strong profitability, excellent cash generation, and a conservatively levered balance sheet. Revenue growth of 6.0% is solid for a large healthcare company, while margins and free cash flow remain strong. The sharp net income increase is positive but likely less representative of underlying operating momentum than the steadier revenue and cash flow profile.
Why Buy Johnson & Johnson Stock? JNJ Key Strengths
- Exceptional profitability: 28.5% net margin and 67.9% gross margin exceed pharmaceutical industry standards
- Outstanding cash generation: $19.7B free cash flow with 20.9% FCF margin demonstrates sustainable earnings quality
- Superior capital efficiency: 32.9% ROE and 13.5% ROA indicate excellent returns on invested capital
- Fortress balance sheet: 210x interest coverage and 0.51x debt/equity provide substantial financial flexibility
- Significant earnings growth: 90.6% YoY net income increase shows strong operational momentum
- Solid revenue growth: 6.0% YoY revenue expansion in mature pharmaceutical sector is respectable
- Excellent profitability, with 67.9% gross margin, 34.6% operating margin, and 28.5% net margin
- Strong cash generation, including $24.53B in operating cash flow and $19.70B in free cash flow
- Healthy financial position, supported by moderate debt/equity of 0.51x and very high interest coverage of 210.2x
JNJ Stock Risks: Johnson & Johnson Investment Risks
- Tight liquidity position: 1.03x current ratio and 0.77x quick ratio suggest limited short-term flexibility
- High debt load: $41.4B long-term debt represents 50.8% of equity, though well-covered by cash flows
- Significant insider activity: 31 Form 4 filings in 90 days warrants monitoring for potential management concerns
- Net income growth far exceeds revenue growth, which may indicate earnings volatility or non-recurring items affecting comparability
- Liquidity is adequate but not especially strong, with a 1.03x current ratio and 0.77x quick ratio
- Top-line growth is respectable but not fast, so future returns depend on sustaining margins and execution
Key Metrics to Watch
- Operating cash flow sustainability and trends relative to net income
- Current ratio and working capital dynamics to assess liquidity improvements
- Debt reduction pace and interest coverage stability
- Revenue growth acceleration in key therapeutic areas
- Free cash flow conversion and capital allocation decisions
- Organic revenue growth and segment-level sales mix
- Free cash flow conversion and operating margin stability
Johnson & Johnson (JNJ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
JNJ Profit Margin, ROE & Profitability Analysis
JNJ vs Healthcare Sector: How Johnson & Johnson Compares
How Johnson & Johnson compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Johnson & Johnson Stock Overvalued? JNJ Valuation Analysis 2026
Based on fundamental analysis, Johnson & Johnson appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Johnson & Johnson Balance Sheet: JNJ Debt, Cash & Liquidity
JNJ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Johnson & Johnson's revenue has shown modest growth of 0% over the 5-year period. The most recent EPS of $13.72 reflects profitable operations.
JNJ Revenue Growth, EPS Growth & YoY Performance
JNJ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $22.5B | $2.7B | $1.11 |
| Q2 2025 | $22.4B | $4.7B | $1.93 |
| Q1 2025 | $21.4B | $3.3B | $1.34 |
| Q3 2024 | $21.4B | $2.7B | $1.11 |
| Q2 2024 | $21.5B | $4.7B | $1.93 |
| Q1 2024 | $20.9B | -$68.0M | $-0.03 |
| Q3 2023 | $20.0B | $4.5B | $1.68 |
| Q2 2023 | $24.0B | $4.8B | $1.80 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Johnson & Johnson Dividends, Buybacks & Capital Allocation
JNJ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Johnson & Johnson (CIK: 0000200406)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JNJ
What is the AI rating for JNJ?
Johnson & Johnson (JNJ) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JNJ's key strengths?
Claude: Exceptional profitability: 28.5% net margin and 67.9% gross margin exceed pharmaceutical industry standards. Outstanding cash generation: $19.7B free cash flow with 20.9% FCF margin demonstrates sustainable earnings quality. ChatGPT: Excellent profitability, with 67.9% gross margin, 34.6% operating margin, and 28.5% net margin. Strong cash generation, including $24.53B in operating cash flow and $19.70B in free cash flow.
What are the risks of investing in JNJ?
Claude: Tight liquidity position: 1.03x current ratio and 0.77x quick ratio suggest limited short-term flexibility. High debt load: $41.4B long-term debt represents 50.8% of equity, though well-covered by cash flows. ChatGPT: Net income growth far exceeds revenue growth, which may indicate earnings volatility or non-recurring items affecting comparability. Liquidity is adequate but not especially strong, with a 1.03x current ratio and 0.77x quick ratio.
What is JNJ's revenue and growth?
Johnson & Johnson reported revenue of $94.2B.
Does JNJ pay dividends?
Johnson & Johnson does not currently pay dividends.
Where can I find JNJ SEC filings?
Official SEC filings for Johnson & Johnson (CIK: 0000200406) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JNJ's EPS?
Johnson & Johnson has a diluted EPS of $11.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JNJ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Johnson & Johnson has a BUY rating with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is JNJ stock overvalued or undervalued?
Valuation metrics for JNJ: ROE of 32.9% (sector avg: 15%), net margin of 28.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy JNJ stock in 2026?
Our dual AI analysis gives Johnson & Johnson a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is JNJ's free cash flow?
Johnson & Johnson's operating cash flow is $24.5B, with capital expenditures of $4.8B. FCF margin is 20.9%.
How does JNJ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 28.5% (avg: 12%), ROE 32.9% (avg: 15%), current ratio 1.03 (avg: 2).
Why is JNJ's return on equity (ROE) so high?
Johnson & Johnson has a return on equity of 32.9%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 28.5% net margin.